Novo Nordisk reported DKK1.53B in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Bausch Health Companies USD 397M 15M Dec/2025
Bristol-Myers Squibb USD 411M 21M Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
GlaxoSmithKline GBP 167M 21M Mar/2026
Merck USD 479M 67M Mar/2026
Novartis USD 343M 39M Mar/2026
Novo Nordisk DKK 1.53B 3.43B Sep/2025
Pacira USD 3.7M 193K Mar/2026
Sanofi EUR 178M 203M Mar/2026
Supernus Pharmaceuticals USD 910K 278K Jun/2023